OTC Markets · Healthcare
Interpace Biosciences stock from India: price, numbers and tax
Interpace Biosciences (IDXG) is not currently available to trade on Paasa; this guide covers the price, the numbers and the Indian tax treatment.
By Paasa · Updated
Interpace Biosciences at a glance
- Price
- $4.50-$0.93 (17.13%)
- Market cap
- $26.56M
- Day range
- $4.50 – $5.39
- P/E
- 0.18
- Dividend yield
- None
- Volume
- 5.48K
- 1 month
- -10.00%
- 6 months
- -50.00%
- YTD
- -26.83%
- 1 year
- -2.39%
- 5 years
- -88.39%
Interpace Biosciences statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $38.7M | $46.9M | $40.2M | $31.8M | $41.3M |
| Gross profit | $24.1M | $29.9M | $23.9M | $18.2M | $17.9M |
| Operating income | $4.1M | $8.1M | $2.8M | −$3.8M | −$11.7M |
| Net income | $24.6M | $6.7M | $802.0K | −$5.9M | −$14.7M |
| Earnings per share | $27.75 | $7.10 | $0.95 | −$6.90 | −$17.85 |
| EBITDA | $4.8M | $8.4M | $4.4M | −$2.3M | −$1.3M |
| Total assets | $33.8M | $14.8M | $13.0M | $16.0M | $38.4M |
| Total debt | $1.2M | $5.9M | $11.2M | $16.1M | $10.7M |
| Cash and short-term investments | $2.5M | $1.5M | $3.5M | $4.8M | $3.3M |
| Shareholders' equity | $22.4M | −$2.2M | −$15.1M | −$63.1M | −$42.4M |
| Operating cash flow | $5.8M | $4.6M | $3.8M | −$7.7M | −$8.7M |
| Free cash flow | $5.5M | $3.8M | $3.3M | −$8.0M | −$9.1M |
| Capital expenditure | −$356.0K | −$876.0K | −$470.0K | −$322.0K | −$354.0K |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in USD; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Guardant Health | GH | $146.76 | $19.85B |
| NeoGenomics | NEO | $15.16 | $1.96B |
| Personalis | PSNL | $14.79 | $1.60B |
| Castle Biosciences | CSTL | $33.78 | $1.04B |
Peers as grouped by the data provider. This is not an investment recommendation.
Analyst price targets
- Low
- —
- High
- —
- Median
- —
- Consensus
- —
Ratings: 6 buy · 1 hold · 0 sell. Consensus: Buy.
Published sell-side 12-month targets in USD, aggregated by the data provider. They are not Paasa's view and not a forecast.
Why invest in Interpace Biosciences from India
What Interpace Biosciences does
Interpace Biosciences, Inc. is a U.S.-based company specializing in advanced molecular diagnostic tests, bioinformatics, and pathology services, primarily focused on assessing cancer risk. Among its key offerings is PancraGEN, a comprehensive genomic test for pancreatic cysts and solid lesions within the pancreaticobiliary system. Interpace Biosciences operates in the Medical - Diagnostics & Research industry within the Healthcare sector.
Hold a dollar asset
Interpace Biosciences shares are priced in US dollars, so a weaker rupee adds to what they're worth in rupees. The rupee depreciated over 85% against the dollar between 2010 and 2025.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
What tax do I pay in India when I sell Interpace Biosciences shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the USD/INR rate on the day you bought and the day you sold, so the currency move is part of the gain.